Artelo Biosciences (ARTL) AI Stock Analysis

• Market Cap: $8.64M
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.19
• Revenue Growth: N/A
• EPS Growth: 14.28%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -4.32
• Shares Outstanding: 704,425
• 10 Day Avg. Volume: 115,020
• 30 Day Avg. Volume: 1,315,137
• PEG Ratio: N/A
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.27
• Enterprise Value/Market Cap: 0.38
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.08
• 1Y Price Target: $20.00
• Price Target Upside: 63.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 34 Underperform
• Price Target: ―

Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.

Positive Factors

Clinical Milestones

Artelo's pipeline candidates are slated to reach important clinical milestones, which are underappreciated.

Investigational Drug

ART27.13 is emerging as a high-value investigational drug, as no therapies have proven to be safe treatments and approved for cancer-related cachexia.

Negative Factors

Investment Risks

Investment thesis risks include failure of clinical trials to prove efficacy and potential need to raise additional funds.

Artelo Biosciences Business Overview & Revenue Model

Company Description

Artelo Biosciences (ARTL) is a biopharmaceutical company focused on the development and commercialization of proprietary therapeutics targeting lipid signaling pathways, including the endocannabinoid system. The company operates in the biotechnology sector and is engaged in creating a diverse pipeline of products aimed at treating cancer, pain, and other serious medical conditions. Artelo's core products are in various stages of development, leveraging novel approaches to modulate the body's response to disease.

How the Company Makes Money

Artelo Biosciences generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company's revenue model is largely based on achieving clinical and regulatory milestones that can attract licensing deals or partnerships with larger pharmaceutical companies. These partnerships may result in upfront payments, milestone payments, and royalties on sales of successfully commercialized products. Artelo may also seek government grants or research funding to support its development programs. As a company focused on drug development, its earnings are contingent on successful clinical trials, regulatory approvals, and market adoption of its therapies.

Artelo Biosciences Financial Statement Overview

Summary

Artelo Biosciences faces significant financial challenges with continuous losses and no revenue generation. The low debt is a positive aspect, but declining assets and equity raise concerns about long-term sustainability. Cash flow issues further underscore the need for strategic financial management to improve its financial health.

Income Statement

Artelo Biosciences has consistently reported zero revenue, indicating no current commercial products. The company has a high negative EBIT and Net Income, reflecting continuous losses. The absence of revenue growth constrains its ability to improve financial performance in the short term.

Balance Sheet

The company maintains a low debt-to-equity ratio, which is favorable and indicates low financial leverage. However, there is a significant decline in total assets and stockholders' equity over time, suggesting potential financial instability.

Cash Flow

Artelo Biosciences shows negative operating and free cash flows, indicating cash burn. However, there was a positive cash flow from investing activities due to asset sales. The continuous negative cash flows highlight liquidity challenges.

Breakdown	Dec 2022	Sep 2021	Sep 2020	Sep 2019	Sep 2018
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-10.29M	-7.44M	-4.71M	-4.22M	-2.34M
Net Income	-10.08M	-7.44M	-4.65M	-2.17M	-2.34M
Balance Sheet
Total Assets	20.42M	12.63M	4.38M	6.48M	397.00K
Cash, Cash Equivalents and Short-Term Investments	17.53M	10.06M	2.14M	4.42M	337.42K
Total Debt	63.00K	95.00K	0.00	0.00	0.00
Total Liabilities	1.02M	593.00K	502.18K	1.02M	531.97K
Stockholders Equity	19.40M	12.04M	3.87M	5.46M	-134.97K
Cash Flow
Free Cash Flow	-8.01M	-6.14M	-4.35M	-4.29M	-1.61M
Operating Cash Flow	-8.01M	-6.14M	-4.35M	-2.79M	-1.61M
Investing Cash Flow	2.96M	-3.44M	0.00	-1.50M	-845.00
Financing Cash Flow	0.00	14.11M	1.98M	8.38M	1.39M

Artelo Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 12.27
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTL, the sentiment is Neutral. The current price of 12.27 is below the 20-day moving average (MA) of 15.76, above the 50-day MA of 10.29, and above the 200-day MA of 7.45, indicating a neutral trend. The MACD of 0.69 indicates Positive momentum. The RSI at 47.40 is Neutral, neither overbought nor oversold. The STOCH value of 20.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARTL.

Artelo Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LCTX	61 Neutral	$244.34M	―	-21.40%	―	19.42%	40.83%
Sector *	52 Neutral	$7.47B	0.53	-62.70%	2.38%	14.92%	0.82%
CRBP	43 Neutral	$113.43M	―	-44.89%	―	―	64.71%
SLNO	37 Underperform	$4.43B	―	-105.54%	―	―	-43.20%
BTAI	37 Underperform	$10.30M	―	82.91%	―	64.20%	73.71%
EDSA	35 Underperform	$16.38M	―	-58.78%	―	―	-126.54%
ARTL	34 Underperform	$8.64M	―	-190.70%	―	―	14.28%